{
    "clinical_study": {
        "@rank": "8340", 
        "arm_group": [
            {
                "arm_group_label": "Naftopidil Group", 
                "arm_group_type": "Experimental", 
                "description": "Naftopidil medication patients"
            }, 
            {
                "arm_group_label": "Tamsulosin Goup", 
                "arm_group_type": "Active Comparator", 
                "description": "Tamsulosin medication  patients"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate efficacy and safety of naftopidil in patient with\n      neurogenic lower urinary tract dysfunction not caused by benign prostatic hyperplasia."
        }, 
        "brief_title": "Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neurogenic Lower Urinary Tract Dysfunction", 
        "condition_browse": {
            "mesh_term": "Prostatic Hyperplasia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female aged 20 years old and above (upper limit of age: 80 years old)\n\n          2. patients diagnosed as neurogenic bladder due to cerebrovascular accident, parkinson\n             disease, spinal cord lesion, diabetic neuropathy etc)\n\n          3. a+b\n\n               1. IPSS \u2265 12 and QoL \u2265 3\n\n               2. Maximum Flow Rate <15 mL/s  (Voiding volume) \u2265 120mL)\n\n          4. Ability and willingness to correctly complete the micturition diary and questionnaire\n\n          5. Capable of understanding and having signed the informed consent form after full\n             discussion of the research nature of the treatment and its risks and benefits\n\n        Exclusion Criteria:\n\n          1. In male aged 50 years old  and above, bladder outlet obstruction (Bladder Outlet\n             Obstruction Index(BOOI) \u226540)\n\n          2. In female, Pelvic Organ Prolapse ICS stage; POP-Q stage \u2265 2\n\n          3. In female, the history of anti-incontinence operation.\n\n          4. Patients with cancer of any type including cancer of the prostate or bladder\n\n          5. Patients with urethral stricture or bladder neck contracture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "204", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034604", 
            "org_study_id": "2013-02-043"
        }, 
        "intervention": [
            {
                "arm_group_label": "Naftopidil Group", 
                "intervention_name": "Naftofidil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Tamsulosin Goup", 
                "intervention_name": "Tamsulosin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naftopidil", 
                "Tamsulosin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Naftopidil", 
            "safety"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "ksleedr@skku.edu", 
                "last_name": "Kyu-Sung Lee, M.D., Ph.D.", 
                "phone": "82-2-3410-3554"
            }, 
            "contact_backup": {
                "email": "khdoct29@gmail.com", 
                "last_name": "Hyun Wook You, M.D.", 
                "phone": "82-2-3410-1268"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "130-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyu-Sung Lee, Ph.D, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "keleedr@skku.edu", 
            "last_name": "Kyu-Sung Lee, M.D., Ph.D.", 
            "phone": "82-2-3410-3554"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "international prostate symptom score (IPSS) change, except QOL domain scores", 
            "measure": "Changes in patients' symptom questionnaires", 
            "safety_issue": "No", 
            "time_frame": "from baseline to 8 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034604"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "KYU-SUNG LEE", 
            "investigator_title": "professor,MD,PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "maximal flow rate, mean flow rate, voided volume and Changes in uroflowmetry parameters : maximal flow rate,mean flow rate, voided volume and PVR", 
                "measure": "Changes in uroflow parameters", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 8 weeks of treatment"
            }, 
            {
                "measure": "Change in proportion of patients showed an improvement in IPSS total scores of more than 25%.", 
                "safety_issue": "No", 
                "time_frame": "from baseline to 8 weeks of treatment"
            }, 
            {
                "measure": "Benefit, Satisfaction, and Willingness to Continue (BSW) questions", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "measure": "Score of global response assessment for Korean, GRA-K", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "measure": "Treatment satisfaction question, TSQ", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after treatment"
            }, 
            {
                "measure": "safety evaluation : incidence and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "change in each domain scores of IPSS", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }, 
            {
                "measure": "change in number of urinary frequency, nocturia", 
                "safety_issue": "No", 
                "time_frame": "up to 8weeks"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}